PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Identified as a pharmaceutical plant additive for management [PMID:39409183]
Undergone full process of nonclinical and clinical development to deliver therapeutic potential [PMID:35468650]
Reduced body weight, serum triglycerides, total cholesterol, ALT, and hepatic lipid content in mice [PMID:39391981]
Atractylodin ameliorates colitis via PPARα agonism in mice [PMID:36614242]
Atractylodinol reduces bleomycin-induced lung injury and fibrosis in mice [PMID:37641404]
Fuling-Zexie formula (containing A. lancea) attenuates renal injury and inhibits JAK2/STAT3 signaling in mice [PMID:37788785]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 39409183 (2024) — Advances in Gouty Arthritis Management: Integration of Established Therapies, Emerging Treatments, and Lifestyle Interventions. · International journal of molecular sciences
- 2.PMID: 35114907 (2022) — Atractylodes lancea Rhizoma Attenuates DSS-Induced Colitis by Regulating Intestinal Flora and Metabolites. · The American journal of Chinese medicine
- 3.PMID: 37641404 (2023) — Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-β receptor 1 recycling by stabilizing vimentin. · Molecular therapy : the journal of the American Society of Gene Therapy
- 4.PMID: 37788785 (2024) — Fuling-Zexie formula attenuates hyperuricemia-induced nephropathy and inhibits JAK2/STAT3 signaling and NLRP3 inflammasome activation in mice. · Journal of ethnopharmacology
- 5.PMID: 36614242